Articles related to CLINICAL TRIALS

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.

In this pivotal trial, apixaban, when used for subclinical atrial fibrillation, demonstrated a 0.63 hazard ratio for stroke or systemic embolism compared to aspirin, indicating a significant reduction in stroke risk at the expense of increased bleeding risk.

ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.

CARsgen Therapeutics faces a critical juncture as the FDA places a clinical hold on three of its key CAR-T cell therapy candidates, highlighting the paramount importance of manufacturing standards in the realm of advanced oncology treatments.

In a recent study, researchers found that, although pembrolizumab increased the pathological complete response in gastric cancer patients, it did not significantly improve event-free survival.